Upstream Bio, Inc. (UPB)
| Market Cap | 868.80M |
| Revenue (ttm) | 2.21M |
| Net Income (ttm) | -69.59M |
| Shares Out | 53.60M |
| EPS (ttm) | -24.30 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,989,203 |
| Open | 16.64 |
| Previous Close | 16.61 |
| Day's Range | 15.51 - 17.06 |
| 52-Week Range | 14.97 - 29.46 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 56.50 (+248.55%) |
| Earnings Date | Feb 14, 2025 |
About UPB
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts. [Read more]
Analyst Forecast
According to 4 analysts, the average rating for UPB stock is "Strong Buy." The 12-month stock price forecast is $56.5, which is an increase of 248.55% from the latest price.
News
Upstream Bio: Treating Respiratory Disorders With TSLP Targeting Differentiation
Upstream Bio, Inc. raised approximately $293 million in an IPO, positioning it to leverage upstream pathway targeting of TSLP for treatment of patients with respiratory disorders using verekitug. Rele...
Upstream Bio Announces Addition to Russell 2000® Index
WALTHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respirator...
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
Just two weeks ago, Upstream Bio, Inc. UPB closed its upsized initial public offering (IPO) of 17.25 million shares at $17 per share, with gross proceeds of approximately $293 million.
Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
WALTHAM, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on sev...
Upstream Bio valued at $1.1 bln as shares jump in Nasdaq debut
Shares of Upstream Bio opened 26.5% above the initial public offering price in their Nasdaq debut on Friday, valuing the drug developer at $1.05 billion.
Upstream Bio raises $255 mln in US IPO
Upstream Bio , which is developing treatments for some respiratory disorders, said on Thursday it had raised $255 million in its initial public offering in the United States.
Upstream Bio Announces Pricing of Upsized Initial Public Offering
WALTHAM, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on sev...
Respiratory disorder biotech Upstream Bio files for a $100 million IPO
Upstream Bio, a clinical-stage biotech developing a monoclonal antibody to target respiratory disorders, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering.
Upstream Bio IPO Registration Document (S-1)
Upstream Bio has filed to go public with an IPO on the NASDAQ.